NeoGenomics, Inc., a prominent provider of oncology testing services, has announced the commercial launch of its c-MET CDx assay for advanced non-small cell lung cancer (NSCLC). This companion diagnostic immunohistochemistry $(IHC)$ assay is designed to assist in the treatment selection for NSCLC patients by detecting c-Met protein overexpression, a biomarker found in up to 50% of advanced NSCLC cases. The assay delivers rapid results within 48 hours, aiding in timely clinical decision-making. It supports patient eligibility for newly approved targeted therapies, including EMRELIS™ (telisotuzumab vedotin-tllv), approved by the U.S. FDA for adults with previously treated advanced NSCLC exhibiting high c-MET protein overexpression. This launch expands NeoGenomics' comprehensive NSCLC testing portfolio, aligning with evolving precision cancer care standards. For further details, visit NeoGenomics' official website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.